HIV Clinical Trial
Official title:
Treating South African Pregnant Women for Methamphetamine
The purpose of this study was to develop and initially evaluate an efficacious, comprehensive, culturally sensitive, women-centered model of care for pregnant South African women by adapting and refining PI Jones' Reinforcement-Based Treatment (RBT) model, at the same time integrating into it the HIV prevention components of Co-I Wechsberg's Women's Health CoOp (WHC) model, yielding an integrated treatment and prevention model, RBT+WHC.
Cape Town is a striking example of the need for women-specific substance abuse treatment, as
it is experiencing a devastating level of methamphetamine use (7% of the adult
population),especially among women of childbearing age. The use of methamphetamine
(hereafter referred to as "meth") is higher in Cape Town than anywhere else in the country.
Consequently, there has been a critical need to develop and test a woman-focused
intervention that reduces meth use in a highly vulnerable population of South African women.
Since 2001, the Women's Health CoOp (WHC; PI Wechsberg; RO1s DA011609S; AA014488; HD058320)
has successfully adapted an evidence-based intervention to reduce sex- and drug-risk
behaviors in drug-using South African women. However, with a rapid rise in meth use, the
Western Cape is experiencing a new drug epidemic. A previous WHC study data indicated that
the WHC had limited success in reducing the use of this among women. Alarmingly, among WHC
participants, a greater proportion of pregnant than non-pregnant women reported using meth
(n=24/26=92%; n=238/356=67%; p=.01). These findings are underscored by a lack of a focused
and intensive treatment for meth-using pregnant women who live in impoverished townships.
Thus, this project responded to PA-09-021 International Research Collaboration on Drug Abuse
and Addiction Research (R21) by developing treatment options for meth use among pregnant
women and using the long collaboration between WHC staff and local treatment providers to
develop our first project to treat meth use in pregnant women.
The goal of this project was to develop and initially evaluate an efficacious,
comprehensive, culturally sensitive, women-centred model of care for pregnant South African
women by adapting and refining PI Jones' Reinforcement-Based Treatment (RBT) model, at the
same time integrating into it the HIV prevention components of Co-I Wechsberg's Women's
Health CoOp (WHC) model, yielding an integrated treatment and prevention model, RBT+WHC.
The study had two sequential aims: Aim 1: Adapt and pretest a comprehensive drug abuse
treatment model, RBT, which integrated the evidence-based WHC HIV prevention model, to
produce a comprehensive, culturally sensitive, woman-focused intervention for meth-using
pregnant Coloured women, RBT+WHC. Aim 2: Conduct a small-scale randomized controlled trial
(RCT) with pregnant Coloured women to determine the acceptability, feasibility, and initial
efficacy of the RBT+WHC model relative to a psycho-educational control condition in terms of
their respective impact on maternal outcomes, including (a) meth use, (b) frequency of
unprotected sex acts, and (c) number of prenatal care visits; and neonatal outcomes
including (d) length of hospital stay, (e) birth weight, and (f) gestational age at
delivery. About 300 women were screened for the study but only 32 were found to eligible and
completed the study.
The public health impact of this project was far-reaching. RBT+WHC aimed to fill a critical
gap in substance use treatment research in a social structure where women are
disproportionately disenfranchised from receiving healthcare compared with men. Furthermore,
this initial study laid the foundation for a full-scale RCT to examine the impact of RBT+WHC
on an array of maternal and neonatal outcomes, within the population of pregnant Coloured as
well as Black and White South African women.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |